PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma

This study tests a PET scan-guided treatment approach for people newly diagnosed with advanced Hodgkin lymphoma. Patients start with an immunotherapy drug called Nivolumab, and the treatment is then adjusted based on how well the cancer responds on a PET scan — aiming to reduce chemotherapy exposure while maintaining effectiveness. **You may be eligible if...** - You are 18–60 years old - You have newly diagnosed classical Hodgkin lymphoma at stage IIB (bulky), III, or IV - You have not yet received any chemotherapy, radiation, or immunotherapy for lymphoma - You have at least one tumor measuring 15 mm or more on a CT scan - Your heart, lungs, liver, and kidneys are functioning adequately **You may NOT be eligible if...** - You have active hepatitis B or C, or HIV - You are pregnant or breastfeeding - You have had a prior or currently active autoimmune disease Talk to your doctor to see if this trial is right for you.